Edition:
United Kingdom

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

2.60USD
20 Jul 2018
Change (% chg)

$0.05 (+1.96%)
Prev Close
$2.55
Open
$2.55
Day's High
$2.60
Day's Low
$2.53
Volume
8,398
Avg. Vol
20,516
52-wk High
$3.95
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Tracon Pharmaceuticals CEO Charles Theuer Appointed As Principal Financial Officer
Friday, 15 Jun 2018 

June 15 (Reuters) - TRACON Pharmaceuticals Inc ::TRACON PHARMACEUTICALS - EFFECTIVE UPON PATRICIA BITAR'S RESIGNATION, CHARLES P. THEUER, CO'S CEO, WAS APPOINTED AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Tracon Pharmaceuticals Inc ::AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA.AMBRX INC - ENTERED INTO LICENSING AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION OF TRACON'S PROPRIETARY ENDOGLIN ANTIBODY, TRC105 IN CHINA.AMBRX SAYS TRANSACTION GRANTS AMBRX EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE TRC105 IN ALL INDICATIONS IN CHINA AND TAIWAN.AMBRX SAYS UNDER DEAL TERMS, TRACON WILL RECEIVE AN UPFRONT PAYMENT OF $3 MILLION.AMBRX SAYS TRACON IS ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES FROM HIGH SINGLE DIGITS TO LOW TEENS ON NET SALES OF TRC105 IN AMBRX TERRITORIES.  Full Article

Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Tracon Pharmaceuticals Inc ::Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget.Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​.Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity​.  Full Article

Tracon Pharma reports third quarter financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports third quarter financial results and provides corporate update.Tracon Pharmaceuticals Inc-qtrly ‍shr $0.07​.  Full Article

Tracon pharmaceuticals announces successful meetings with FDA, EMA for TRC105 in Angiosarcoma
Monday, 3 Oct 2016 

Tracon Pharmaceuticals Inc : Reached agreement with both regulatory agencies regarding key elements of phase 3 program for trc105 in angiosarcoma . Tracon pharmaceuticals announces successful meetings with fda and ema for trc105 (carotuximab) in angiosarcoma .Expects to initiate enrollment in phase 3 study by year-end.  Full Article

Tracon Pharma qtrly loss per share $0.68
Wednesday, 10 Aug 2016 

Tracon Pharmaceuticals Inc : Tracon pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Tracon pharmaceuticals inc says collaboration revenue for q2 of 2016 was $0.8 million, compared to $4.2 million for q2 of 2015 . Qtrly loss per share $0.68 .Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Tracon Pharmaceuticals Files For Offering Of Up To 27.4 Mln Shares Of Common Stock By The Selling Stockholders

* TRACON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 27.4 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS Source text: [https://bit.ly/2KQef7f] Further company coverage: